Depakine® sodium di-n-propylacetate is a new anti-epileptic drug. Its action may be related to inhibition of GABA-transaminase. We report our results with Depakine treatment in 33 patients with Petit Mal, myoclonic Petit Mal, Grand Mal and focal epilepsy. We can confirm the results of other authors concerning the beneficial effects on Petit Mal, myoclonic Petit Mal and on certain cases of other forms of epilepsy. Clinical effects were often paralleled by improvement in the EEG. The only side effects noted were occasional gastrointestinal disturbances. Although these results should be confirmed in a larger series of patients, we believe that Depakine represents a valuable contribution to the therapy of epilepsy.